Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding pharmacokinetic study of L19IL2 in advanced solid tumours
2005-002716-16Phase 2Completed
- Sponsor
- Philogen
- Start
- Feb 2006
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darleukin in Nonhematologic neoplasms and renal cell carcinoma (RCC), sponsored by Philogen. Primary endpoints: Pharmacokinetics of L19IL2 and Dose-finding and tolerability. Started Feb 2006; status: completed.
02
Drugs
darleukin
03
Conditions
Nonhematologic neoplasmsrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2005-002716-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002716-16.